公开(公告)号：CA2709081C

公开(公告)日：2016-03-22

申请号：CA2709081

申请日：2008-12-05

Applicant: ABBOTT LAB

Inventor： LIU HUAQING ,  BLACK LAWRENCE A ,  BENNANI YOUSSEF L ,  COWART MARLON D ,  TIAN ZHENPING ,  BRACKEMEYER PAUL J

IPC: C07D295/14 ,  A61K31/40 ,  A61K31/41 ,  A61K31/44 ,  A61P25/00 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: Compounds of formula (I) wherein R1, R2, R3, R3a, R3b, R4, and R5 are defined in the description, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

公开(公告)号：CA2505427C

公开(公告)日：2012-04-03

申请号：CA2505427

申请日：2003-11-05

Applicant: ABBOTT LAB

Inventor： ALTENBACH ROBERT J ,  BLACK LAWRENCE A ,  CHANG SOU-JEN ,  COWART MARLON D ,  FAGHIH RAMIN ,  GFESSER GREGORY A ,  KU YI-YIN ,  LIU HUAQING ,  LUKIN KIRILL A ,  NERSESIAN DIANA L ,  PU YU-MING ,  SHARMA PADAM N ,  BENNANI YOUSSEF L ,  CURTIS MICHAEL P

IPC: C07D471/04 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/445 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/541 ,  A61P3/00 ,  A61P25/00 ,  C07C255/58 ,  C07D207/08 ,  C07D207/12 ,  C07D207/14 ,  C07D207/20 ,  C07D213/30 ,  C07D213/38 ,  C07D213/61 ,  C07D213/64 ,  C07D213/85 ,  C07D215/12 ,  C07D215/14 ,  C07D215/20 ,  C07D217/14 ,  C07D237/12 ,  C07D237/14 ,  C07D237/28 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D239/52 ,  C07D241/12 ,  C07D241/42 ,  C07D263/32 ,  C07D277/28 ,  C07D295/073 ,  C07D295/092 ,  C07D295/096 ,  C07D295/112 ,  C07D295/135 ,  C07D295/155 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

公开(公告)号：MX2010006535A

公开(公告)日：2010-08-31

申请号：MX2010006535

申请日：2008-12-05

Applicant: ABBOTT LAB

Inventor： BENNANI YOUSSEF L ,  BLACK LAWRENCE A ,  COWART MARLON D ,  LIU HUANQING ,  TIAN ZHENPING ,  BRACKEMEYER PAUL J

IPC: C07D295/14 ,  A61K31/40 ,  A61K31/41 ,  A61K31/44 ,  A61P25/00 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: Los compuestos de la fórmula (I) en donde R1, R2, R3, R3a, R3b, R4, y R5 son definidos en la descripción, son útiles para el tratamiento de padecimientos y enfermedades prevenidas por o aliviadas por los ligandos del receptor de histamina-3. También se describen composiciones farmacéuticas que comprenden los ligandos del receptor de histamina-3, métodos para utilizar dichos compuestos y composiciones, y un proceso para preparar los compuestos dentro del alcance de la fórmula (I).

公开(公告)号：ECSP10010253A

公开(公告)日：2010-07-30

申请号：ECSP10010253

申请日：2010-06-14

Applicant: ABBOTT LAB

Inventor： COWART MARLON D ,  LIU HUAQING ,  BLACK LAWRENCE A ,  BENNANI YOUSSEF L ,  BRACKEMEYER PAUL J ,  TIAN ZHENPING

IPC: A61K31/40 ,  A61K31/44 ,  A61P25/00 ,  C07D295/14 ,  C07D401/12 ,  C07D403/12

Abstract: Compuestos con la fórmula (I) donde R1, R2, R3, R3a, R3b, R4, and R5 tienen los valores que se definen en la memoria descriptiva, que son útiles para tratar condiciones o trastornos que se pueden prevenir o mejorar mediante los ligandos del receptor de histamina-3. También se divulgan composiciones farmacéuticas que comprenden los ligandos del receptor de histamina-3, métodos para usar dichos compuestos y composiciones, y un proceso para preparar compuestos dentro del alcance de la fórmula (I).

公开(公告)号：AU2008343115A1

公开(公告)日：2009-07-09

申请号：AU2008343115

申请日：2008-12-18

Applicant: ABBOTT LAB

Inventor： HSIEH GIN C ,  ZHAO CHEN ,  BLACK LAWRENCE A ,  LIU HUAQING ,  COWART MARLON D ,  WAKEFIELD BRIAN D ,  GFESSER GREGORY A ,  ALTENBACH ROBERT J

IPC: C07D413/14 ,  A61K31/423 ,  A61K31/428 ,  A61P3/10 ,  A61P25/00 ,  C07D417/14

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.

公开(公告)号：SK286806B6

公开(公告)日：2009-05-07

申请号：SK5542001

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: C07D237/00 ,  A61K31/00 ,  A61K31/50 ,  A61K31/501 ,  A61P19/00 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/00 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/00 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/00 ,  C07D405/04 ,  C07D405/12 ,  C07D409/00 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/00 ,  C07D413/04 ,  C07D413/12 ,  C07D417/00 ,  C07D417/06

Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (Cox-2), Cox-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (Cox-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for Cox-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs.

公开(公告)号：CA2655604A1

公开(公告)日：2007-12-27

申请号：CA2655604

申请日：2007-06-22

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BENNANI YOUSSEF L ,  COWART MARLON D ,  LIU HUAQING

IPC: C07D207/06 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/4196 ,  A61K31/4365 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/455 ,  A61K31/501 ,  A61K31/506 ,  A61K31/55 ,  A61P25/00 ,  C07D401/10 ,  C07D403/10 ,  C07D417/10 ,  C07D495/04

Abstract: Compounds of formula (I) are useful in treating conditions or disorders p revented by or ameliorated by histamine-3 receptor ligands. Also disclosed a re pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for prepari ng compounds within the scope of formula (I).

公开(公告)号：SA1077B1

公开(公告)日：2006-08-06

申请号：SA98190764

申请日：1998-11-16

Applicant: ABBOTT LAB

Inventor： BASHA ANWER ,  ROHDE JEFFREY J ,  KORT MICHAE L E ,  BLACK LAWRENCE A ,  LIU HUAQING ,  KOLASA TEODOZYJ ,  MCCARTY CATHERINE M ,  PATEL MINA V

IPC: C07D237/14 ,  C07D237/18 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D409/06 ,  C07D409/12 ,  C07D417/06

Abstract: الملخص: يصفالاختراعالراهنمركباتبيريدازينون pyridazinone وهيعبارةعنمثبطاتأنزيمالأكسجةالحلقية (سيكلوأكسجيناز) cyclooxygenase inhibitors (cox)،وبصفةخاصةهيعبارةعنمثبطاتانتقائية selective inhibitors لإنزيمالأكسجةالحلقية-٢ (2/cyclooxygenase-2 (COX؛و COX-2 هونظيرالشكلالقابلللحث inducible isoform المقترنبالالتهاب inflammation وهومعاكسلنظيرالشكلالأساسي constitutive isoform؛الذيهوعبارةعنأنزيمالأكسجةالحلقية- ١ (1-cyclooxygenase-l (COX وهوانزيمتهيين &"housekeeping&" enzyme) فيالعديدمنالأنسجة tissues؛بمافيذلكالقناةالهضمية gastrointestinal (GI) tract والكليتين kidneys. وتقللانتقائيةهذهالمركباتنحو -COX2 التأثيراتالجانبيةغيرالمرغوبةفيالقناةالهضميةوالكليتينالملاحظةعنداستخدامالعقاقيرالمضادةللالتهابغيرالستيرويدية -non-steroidal anti (inflammatory drugs (NSAIDs المسوقةحاليا

公开(公告)号：ES2249919T3

公开(公告)日：2006-04-01

申请号：ES99953259

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: Un compuesto seleccionado entre el grupo compuesto por 2-(4-Fluorofenil)-4-(4-hidroxi-2-metil-1-butoxi)-5-[4-(metilsulfonil)fenil]-3(2H)-piridazinona; o una sal o éster farmacéuticamente aceptable de los mismos.

公开(公告)号：NO318623B1

公开(公告)日：2005-04-18

申请号：NO20012061

申请日：2001-04-26

Applicant: ABBOTT LAB

Inventor： PATEL MEENA V ,  BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  ROHDE JEFFREY J ,  STEWART ANDREW O ,  MCCARTY CATHERINE M ,  COGHLAN MICHAEL J ,  LIU HUAQING

IPC: A61K31/50 ,  A61K31/501 ,  A61P19/02 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  C07D237/14 ,  C07D237/16 ,  C07D237/18 ,  C07D237/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/06

Abstract: The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).